OncoMatch/Clinical Trials/NCT03943004
Trial of DFP-14927 in Advanced Solid Tumors
Is NCT03943004 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies DFP-14927 for solid tumor.
Treatment: DFP-14927 — This is a Phase I, open-label, single-arm, dose escalation study of DFP-14927 intravenous infusion administered to patients with refractory or relapsed solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy for the disease
refractory after standard therapy for the disease or for which conventional systemic therapy is not reliably effective or no effective therapy is available
Cannot have received: chemotherapy
Exception: within 4 weeks prior to study entry
previous chemotherapy...within 4 weeks prior to this study entry
Cannot have received: immunotherapy
Exception: within 4 weeks prior to study entry
previous immunotherapy...within 4 weeks prior to this study entry
Cannot have received: radiotherapy
Exception: within 4 weeks prior to study entry
previous radiotherapy...within 4 weeks prior to this study entry
Cannot have received: investigational therapy
Exception: within 4 weeks prior to study entry
previous...any other investigational therapy within 4 weeks prior to this study entry
Cannot have received: nitrosoureas
Exception: within 6 weeks prior to study entry
nitrosoureas...within 6 weeks prior to this study entry
Cannot have received: mitomycin C (mitomycin C)
Exception: within 6 weeks prior to study entry
mitomycin C...within 6 weeks prior to this study entry
Cannot have received: targeted therapies
Exception: within 5 half-lives prior to study entry
targeted therapies prior to this study entry
Cannot have received: extensive prior radiotherapy
Exception: more than 30% of bone marrow reserves
Extensive prior radiotherapy, more than 30% of bone marrow reserves
Cannot have received: bone marrow/stem cell transplantation
prior bone marrow/stem cell transplantation
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 x 10⁹/L; platelets ≥ 100 x 10⁹/L; hemoglobin ≥ 9.0 g/dL (transfusions permissible)
Kidney function
plasma creatinine ≤ 1.5 x ULN or calculated clearance ≥ 60 mL/min (Cockcroft-Gault formula)
Liver function
total bilirubin ≤ 1.5 x ULN; ALT and AST < 2.5 x ULN (<5 x ULN if documented hepatic metastases)
Cardiac function
prothrombin time (PT) ≤1.2 x ULN, partial thromboplastin time (PTT) ≤ 1.2 ULN, INR ≤ 1.5; QTc < 450 msec for men and < 470 msec for women (up to 500 msec acceptable if well controlled)
Adequate clinical laboratory values defined as: absolute neutrophil count ≥ 1.5 x 10⁹/L; platelets ≥ 100 x 10⁹/L; hemoglobin ≥ 9.0 g/dL (transfusions permissible); plasma creatinine ≤ 1.5 x ULN or calculated clearance ≥ 60 mL/min (Cockcroft-Gault formula); total bilirubin ≤ 1.5 x ULN; ALT and AST < 2.5 x ULN (<5 x ULN if documented hepatic metastases); prothrombin time (PT) ≤1.2 x ULN, partial thromboplastin time (PTT) ≤ 1.2 ULN, and international normalized ratio (INR) ≤ 1.5
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA Department of Medicine- Hematology/Oncology · Los Angeles, California
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify